Exploring the Use of Biologics in the Management of Lupus Nephritis: A Clinical Case Conference
Webcast
1 AMA PRA Category 1 Credit™ ...Faculty
OVERVIEW
Exploring the Use of Biologics in the Management of Lupus Nephritis: A Clinical Case Conference is organized by i3 Health.
Dates Available:
February 19, 2026 - February 18, 2027
Statement of Need:
Lupus nephritis is a severe complication that develops in up to 60% of individuals with systemic lupus erythematosus (SLE). Characterized by kidney inflammation and chronic parenchymal damage, lupus nephritis leads to progressive kidney damage and potential kidney failure, representing one of the leading causes of morbidity and mortality among patients with SLE. The emergence of novel biological agents and combination therapies has provided a promising new approach to the treatment of lupus nephritis. This Clinical Case Conference will explore 3 complex case studies illustrating the use of novel therapies and combinations in the management of lupus nephritis (Wiegley et al, 2024). It features perspectives from Anca Askanase, MD, Professor of Medicine, Director of the Lupus Center, and Director of Rheumatology Clinical Trials at Columbia University Irving Medical Center; Andrew Bomback, MD, MPH, Associate Professor of Medicine and Co-Director of the Center for Glomerular Diseases at Columbia University Irving Medical Center; and Samir Parikh, MD, Clinical Professor of Internal Medicine in the Division of Nephrology at The Ohio State University Wexner Medical Center.
Learning Objectives:
Upon completion of this activity, participants should be able to:
- Describe unmet needs in the current management of LN
- Analyze the mechanisms by which new and emerging biologic agents address LN pathophysiology
- Evaluate the clinical utility of novel and emerging biologic therapies for the treatment of patients with LN
ACCREDITATION & CREDITS
Jointly Accredited Provider:
In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians:
i3 Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.
Physician Assistants/Associates:
i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until 2/18/27. PAs should only claim credit commensurate with the extent of their participation.
Nurse Practitioners:
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
TARGET AUDIENCE
PhysicianNursingNephrologistsHealthcare ProvidersNurse PractitionersRheumatologistsAdvanced Practice ProvidersSPECIALITIES
NephrologyRheumatology
Download eMedEvents Mobile App
Track your CE certificates and CME requirements anytime, anywhere.
RELATED ONLINE COURSES
Quick Links